OpenAI has acquired Orchestra Bio, an AI-powered platform that helps biopharma teams coordinate the drug development process.
OpenAI announced the deal Oct. 20 and did not disclose financial terms. The company plans to combine Orchestra’s team and technology with Rosalind, its suite of AI models and tools for life sciences research, which includes the GPT-Rosalind reasoning model and Rosalind Workbench.
Orchestra Bio’s platform lets scientists and program leaders hand off the monitoring and tracking of studies to AI agents. When a problem hits one part of a drug program, such as a failed manufacturing batch that could delay the start of a clinical trial, the agents identify which activities and timelines are affected, gather relevant information and compare response options. Scientists and program leaders then decide how to proceed.
OpenAI said the combined effort aims to build agents that connect scientific findings to the studies, decisions and next steps needed to advance a potential medicine.
The deal targets a lengthy process. Bringing a new drug from target discovery to U.S. regulatory approval takes roughly 10 to 15 years on average, according to OpenAI.
The acquisition extends OpenAI’s push into life sciences, which includes work with Novo Nordisk and Moderna aimed at speeding research and development.
The post OpenAI acquires AI drug development platform appeared first on Becker's Hospital Review | Healthcare News & Analysis.